Please assess the completion status of the following clinical trial:

Trial Title: Weekly Dosing of Malarone ® for Prevention of Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening~* Free of clinically significant health problems~* Baseline ECG before entering into the study~* Available to participate for duration of study (approximately 4 months, not including screening period)~* If the participant is female, not pregnant or lactating and willing to use contraception to prevent pregnancy~* BMI between 19 and 30~Exclusion Criteria:~* History of malaria or travel to a malarious country within the previous 12 months~* History of participation in a study in which potential exposure to malaria or vaccination against malaria occurred.~* Planned travel to malarious areas during the study period.~* History of malaria chemoprophylaxis within 60 days prior to time of study entry.~* Chronic use of antibiotics with anti-malarial effects~* Chronic use (defined as more than 14 days)of immunosuppressants or other immune-modifying drugs within six months of study entry.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, ECG or laboratory screening tests~* Significant unexplained anemia~* History of sickle cell disease or sickle cell trait~* Seropositive for hepatitis B or hepatitis C~* History of splenectomy~* Pregnant or lactating female, or female who intends to become pregnant during the study~* Suspected or known current alcohol abuse as defined by the American Psychiatric Association in DSM IV~* History of a neuropsychiatric disorder (anxiety, depression, psychosis, schizophrenia)~* Chronic or active illicit and/or intravenous drug use~* History of allergy to atovaquone, proguanil or chloroquine~* History of psoriasis~* Concurrent participation in other research studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Drug (Type: EXPERIMENTAL): 5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge
- Control -no prophylaxis (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).